Zealand Pharma CEO before possible approval: We can take major leap

These weeks, Zealand Pharma is on the cusp of getting a crucial FDA approval. If the firm successfully attains this, it may transform the company, according to CEO Emmanuel Dulac.

Zealand Pharma President & CEO Emmanuel Dulac | Photo: Stine Bidstrup/ERH

Within the next two weeks, biotech firm Zealand Pharma might get hold of its first own approval. The US Food and Drug Administration (FDA) will present its evaluation on the firm's rescue pen for treating acute low blood sugar in diabetes patients before March 27.

If an approval ensues, the rapidly growing company will be met with a new test of strength:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs